12/31/2024

DIVA Laboratories GmbH

Gentlemen:

In connection with the audit of our financial statements for the year/period ending/ended 12/31/2024, please fill out the attached form to provide directly to our auditors Deloitte & Touche, 20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC, the following information on our holding of your stock:

1. Basic information;
2. Appropriation of earnings;
3. Securities pledged as collateral;
4. Directors;
5. Chair of the board and the chief executive officer; and
6. Outstanding stock.

If the space on the attached form is not enough for your answers, you may use additional sheets.

If you wish to discuss this confirmation request with our auditors, please contact Chao, Freda L. by fax (+886-2-4051-6888 Ext.:5660).

We will appreciate your prompt completion of this form. An addressed reply envelope is enclosed for your reply.

Very truly yours,

DIVA LABORATORIES, LTD.

_____ By:_____

Company Name Authorized Signature(s):

Return To: Chao, Freda L. Group No.: A10B-3 Confirmation No.: LTI-0001
Tel: +886 -2-2725-9988 Ext.: 5660 Fax: +886 -2-4051-6888 Ext.:5660

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Attached is the information on our Company's shares owned by DIVA LABORATORIES, LTD. as of and for the year/period ending/ended 12/31/2024.

DIVA Laboratories GmbH

_____
Company

_____
Signature

_____
Title

_____
Date

Currency: _____

1. Basic information - As of 12/31/2024, the Investor owned the following securities of our company:

   Common stock, 663,923.26 shares, par value - $ 1
   Preferred stock, _____ shares, par value - $ _____
   ☑ Certificates issued: 663,923.26 shares
   ☐ Certificates unissued: _____ shares, composed of _____ shares subscribed in cash and _____ shares of stock dividends.

2. Appropriation of earnings during the year/period ended _____ (please attach the financial statements to this confirmation):

   ☐ Appropriation has not been determined.
   ☐ Earnings were not appropriated.
   ☐ Earnings were appropriated on: _____. The appropriations included:
   Cash dividends distributable to the Investor: $ _____
   Stock dividends distributable to the Investor: $ _____

3. Securities pledged as collateral:

   Name of the pledgee: _____
   Number of shares pledged: _____ shares with total par value of _____
   Date of pledge: _____

4. Directors

   ☐ The Investor is a director of our company.
   Name of the representative: _____
   ☐ The Investor is not a director of our company.

5. Name of the chair of the board: _____

   Name of the chief executive officer: _____

6. As of 12/31/2024, our outstanding stock and related account balances were as follows:

   Common stock, _____ shares
   Preferred stock, _____ shares
   Total shareholders' equity $ _____, net income $ _____
   ☐ The above information was audited by
   Name of accounting firm: _____,
   name of audit partner: _____.
   ☐ The above information was not audited.

7. Other remarks:

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC
Tel：+886 -2-2725-9988 Ext.: 5660 Mobile: +886-937856806
Fax: +886 -2-4051-6888 Ext.:5660 Group: A10B-3 Contact: 趙麟鳳

郵票黏貼處

DIVA Laboratories GmbH

Case No.:

Company Name: DIVA LABORATORIES, LTD.

Confirmation No.: LTI-0001

DIVA Laboratories GmbH

郵票黏貼處

20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Deloitte & Touche

Tel：+886-2-2725-9988 Ext.：5660 Mobile：+886-937856806
Fax：+886-2-4051-6888 Ext.:5660 Group：A10B-3 Contact：趙麟鳳

案件編號：

公司名稱：鈺緯科技開發股份有限公司

函證編號：LTI-0001

12/31/2024

DIVA Laboratories U.S., LLC

Gentlemen:

In connection with the audit of our financial statements for the year/period ending/ended 12/31/2024, please fill out the attached form to provide directly to our auditors Deloitte & Touche, 20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC, the following information on our holding of your stock:

1. Basic information;
2. Appropriation of earnings;
3. Securities pledged as collateral;
4. Directors;
5. Chair of the board and the chief executive officer; and
6. Outstanding stock.

If the space on the attached form is not enough for your answers, you may use additional sheets.

If you wish to discuss this confirmation request with our auditors, please contact Chao, Freda L. by fax (+886-2-4051-6888 Ext.:5660).

We will appreciate your prompt completion of this form. An addressed reply envelope is enclosed for your reply.

Very truly yours,

DIVA LABORATORIES, LTD.

_____ By:_____

Company Name Authorized Signature(s):

Return To: Chao, Freda L. Group No.: A10B-3 Confirmation No.: LTI-0002
Tel: +886 -2-2725-9988 Ext.: 5660 Fax: +886 -2-4051-6888 Ext.:5660

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Attached is the information on our Company's shares owned by DIVA LABORATORIES, LTD. as of and for the year/period ending/ended 12/31/2024.

DIVA Laboratories U.S., LLC

_____
Company

_____
Signature

_____
Title

_____
Date

Currency: _____

1. Basic information - As of 12/31/2024, the Investor owned the following securities of our company:

   Common stock, 1,150,000 shares, par value - $ 1
   Preferred stock, _____ shares, par value - $ _____
   ☑ Certificates issued: 1,150,000 shares
   ☐ Certificates unissued: _____ shares, composed of _____ shares subscribed in cash and _____ shares of stock dividends.

2. Appropriation of earnings during the year/period ended _____ (please attach the financial statements to this confirmation):

   ☐ Appropriation has not been determined.
   ☐ Earnings were not appropriated.
   ☐ Earnings were appropriated on: _____. The appropriations included:
   Cash dividends distributable to the Investor: $ _____
   Stock dividends distributable to the Investor: $ _____

3. Securities pledged as collateral:

   Name of the pledgee: _____
   Number of shares pledged: _____ shares with total par value of _____
   Date of pledge: _____

4. Directors

   ☐ The Investor is a director of our company.
   Name of the representative: _____
   ☐ The Investor is not a director of our company.

5. Name of the chair of the board: _____

   Name of the chief executive officer: _____

6. As of 12/31/2024, our outstanding stock and related account balances were as follows:

   Common stock, _____ shares
   Preferred stock, _____ shares
   Total shareholders' equity $ _____, net income $ _____
   ☐ The above information was audited by
   Name of accounting firm: _____,
   name of audit partner: _____.
   ☐ The above information was not audited.

7. Other remarks:

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC
Tel：+886 -2-2725-9988 Ext.: 5660 Mobile: +886-937856806
Fax: +886 -2-4051-6888 Ext.:5660 Group: A10B-3 Contact: 趙麟鳳

郵票黏貼處

DIVA Laboratories U.S., LLC

Case No.:

Company Name: DIVA LABORATORIES, LTD.

Confirmation No.: LTI-0002

DIVA Laboratories U.S., LLC

郵票黏貼處

20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Deloitte & Touche

Tel：+886-2-2725-9988 Ext.：5660 Mobile：+886-937856806
Fax：+886-2-4051-6888 Ext.:5660 Group：A10B-3 Contact：趙麟鳳

案件編號：

公司名稱：鈺緯科技開發股份有限公司

函證編號：LTI-0002

敬啟者：

勤業眾信聯合會計師事務所受託查核本公司民國 113 年 1 月 1 日至民國 113 年 12 月 31 日財務報表，俾對該財務報表是否足以允當表達本公司之財務狀況及營業成果表示意見。因此敬祈　貴戶詳填隨函所附回件中所載資料後，請於民國 114 年 2 月 7 日前用隨函所附免貼郵資之信封逕寄勤業眾信聯合會計師事務所。

敬請注意：本函僅為核對　貴我雙方往來帳目之用，對於回函，勤業眾信聯合會計師事務所將予保密存檔。

（公司名稱）鈺緯科技開發股份有限公司

（原留印鑑）

敬啟

民國一一四年一月十五日

回件：趙麟鳳 組別：A10B-3 函證編號：LTI-0003
電話：(02)2725-9988 分機：5660 傳真：(02)4051-6888 Ext.:5660

勤業眾信聯合會計師事務所　公鑒：

茲將鈺緯科技開發股份有限公司（以下簡稱該公司）（統一編號：89376900）投資本公司之有關資料，勾選說明如下：

一、截至民國 113 年 12 月 31 日止，該公司投資本公司計普通股 1,745,000 股，每股面額 1 元；及特別股＿＿＿＿＿＿股，每股面額＿＿＿＿元。

☑已領訖股票：1,745,000 股。

□未領訖股票：＿＿＿＿＿＿股，包括現金認購＿＿＿＿＿＿股，盈餘轉增資配股＿＿＿＿＿＿股及資本公積轉增資配股＿＿＿＿＿＿股。

二、本公司＿＿＿＿年度盈餘分配案（請檢附財務報表）

□尚未決議分配　□決議不分配

□已決議分配，分配基準日＿＿＿＿年＿＿月＿＿日，該公司應配得部分如下：

分配項目		股利總額	內含股東可扣抵稅額	股利淨額	股數	是否已領取
現金股利	屬民國 86 年度以前盈餘配發					
	屬民國 87 年度以後盈餘配發					
盈餘轉增資股票股利	屬民國 86 年度以前盈餘配發					
	屬民國 87 年度以後盈餘配發					
資本公積轉增資股票股利						
董監事酬勞						
合計						

三、是否知悉該公司持有之股份設定質權情形：

□否

□是（無該項者，請填「無」字）：

權利人＿＿＿＿＿＿＿＿，質押股數／總面額＿＿＿＿＿＿＿＿

設定日期＿＿＿＿＿＿。

四、董事及監察人

□是本公司董事，代表人為＿＿＿＿＿＿＿＿先生，□不是本公司董事。

□是本公司監察人，代表人為＿＿＿＿＿＿＿＿先生，□不是本公司監察人。

五、本公司董事長為＿＿＿＿＿＿＿＿，總經理為＿＿＿＿＿＿＿＿。

六、本公司截至民國 113 年 12 月 31 日止，已發行普通股＿＿＿＿＿＿股，及特別股＿＿＿＿＿＿股，帳列股東權益總額為＿＿＿＿＿＿＿＿元，帳列本期損益為＿＿＿＿＿＿＿＿元。

□上述資料已經會計師查核，會計師事務所及會計師為＿＿＿＿＿＿＿＿＿＿＿＿。

□上述資料未經會計師查核。

敬啟

＿＿＿＿＿＿＿＿＿＿　＿＿＿＿＿＿＿＿＿＿

（公司章）　（具權限者簽章）

＿＿＿＿＿＿＿＿＿＿

民國　　年　　月　　日　（職稱）

11073
台北市信義區松仁路１００號２０樓
勤業眾信聯合會計師事務所　緘
電話：(02)2725-9988　分機：5660　手機：0937856806
傳真：(02)4051-6888 Ext.:5660　部門：A10B-3　查帳員：趙麟鳳

郵票黏貼處

DIVA CAPITAL INC.　收

案件編號：
公司名稱：鈺緯科技開發股份有限公司
函證編號：LTI-0003

廣告回信
台北郵局登記證
台北廣字第 000348 號

DIVA CAPITAL INC.　緘

IF POSTED IN TAIWAN, MAILER NEED NOT AFFIX POSTAGE STAMP.

	平　信
	限時專送
	掛　號
	限時掛號

11073
台北市信義區松仁路１００號２０樓
勤業眾信聯合會計師事務所　收

電話：(02)2725-9988　分機：5660　手機：0937856806
傳真：(02)4051-6888 Ext.:5660　部門：A10B-3　查帳員：趙麟鳳

案件編號：
公司名稱：鈺緯科技開發股份有限公司
函證編號：LTI-0003

12/31/2024

The Linden Group Corp.

Gentlemen:

In connection with the audit of our financial statements for the year/period ending/ended 12/31/2024, please fill out the attached form to provide directly to our auditors Deloitte & Touche, 20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC, the following information on our holding of your stock:

1. Basic information;
2. Appropriation of earnings;
3. Securities pledged as collateral;
4. Directors;
5. Chair of the board and the chief executive officer; and
6. Outstanding stock.

If the space on the attached form is not enough for your answers, you may use additional sheets.

If you wish to discuss this confirmation request with our auditors, please contact Chao, Freda L. by fax (+886-2-4051-6888 Ext.:5660).

We will appreciate your prompt completion of this form. An addressed reply envelope is enclosed for your reply.

Very truly yours,

DIVA LABORATORIES, LTD.

_____ By:_____

Company Name Authorized Signature(s):

Return To: Chao, Freda L. Group No.: A10B-3 Confirmation No.: LTI-0004
Tel: +886 -2-2725-9988 Ext.: 5660 Fax: +886 -2-4051-6888 Ext.:5660

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Attached is the information on our Company's shares owned by DIVA LABORATORIES, LTD. as of and for the year/period ending/ended 12/31/2024.

The Linden Group Corp.

_____
Company

_____
Signature

_____
Title

_____
Date

Currency: _____

1. Basic information - As of 12/31/2024, the Investor owned the following securities of our company:

   Common stock, 1,000,000 shares, par value - $ 1
   Preferred stock, _____ shares, par value - $ _____
   ☑ Certificates issued: 1,000,000 shares
   ☐ Certificates unissued: _____ shares, composed of _____ shares subscribed in cash and _____ shares of stock dividends.

2. Appropriation of earnings during the year/period ended _____ (please attach the financial statements to this confirmation):

   ☐ Appropriation has not been determined.
   ☐ Earnings were not appropriated.
   ☐ Earnings were appropriated on: _____. The appropriations included:
   Cash dividends distributable to the Investor: $ _____
   Stock dividends distributable to the Investor: $ _____

3. Securities pledged as collateral:

   Name of the pledgee: _____
   Number of shares pledged: _____ shares with total par value of _____
   Date of pledge: _____

4. Directors

   ☐ The Investor is a director of our company.
   Name of the representative: _____
   ☐ The Investor is not a director of our company.

5. Name of the chair of the board: _____

   Name of the chief executive officer: _____

6. As of 12/31/2024, our outstanding stock and related account balances were as follows:

   Common stock, _____ shares
   Preferred stock, _____ shares
   Total shareholders' equity $ _____, net income $ _____
   ☐ The above information was audited by
   Name of accounting firm: _____,
   name of audit partner: _____.
   ☐ The above information was not audited.

7. Other remarks:

Deloitte & Touche
20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC
Tel：+886 -2-2725-9988 Ext.: 5660 Mobile: +886-937856806
Fax: +886 -2-4051-6888 Ext.:5660 Group: A10B-3 Contact: 趙麟鳳

郵票黏貼處

The Linden Group Corp.

Case No.:

Company Name: DIVA LABORATORIES, LTD.

Confirmation No.: LTI-0004

The Linden Group Corp.

郵票黏貼處

20F, Taipei Nan Shan Plaza No. 100, Songren Rd., Xinyi Dist., Taipei 11073, Taiwan, ROC

Deloitte & Touche

Tel：+886-2-2725-9988 Ext.：5660 Mobile：+886-937856806
Fax：+886-2-4051-6888 Ext.:5660 Group：A10B-3 Contact：趙麟鳳

案件編號：

公司名稱：鈺緯科技開發股份有限公司

函證編號：LTI-0004